Autres langues Clarity Pharmaceuticals Ltd

Actions

CU6

AU0000165375

Recherche biotechnologique et médicale

Marché Fermé - Australian S.E. 08:10:26 18/09/2026			Varia. 5j.	Varia. 1 janv.
2,180 ^AUD	+3,81%		-1,36%	-35,50%

27/08	Clarity Pharmaceuticals Ltd publie ses résultats pour l'exercice clos le 30 juin 2026	CI
27/08	Clarity Pharmaceuticals : creusement de la perte sur l'exercice 2026 malgré une hausse du chiffre d'affaires	MT

Autres langues

27/08	Clarity Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2026
27/08	Clarity Pharmaceuticals Fiscal 2026 Loss Widens, Revenue Up
11/08	Bell Potter rates CU6 as Speculative Buy
05/08	Clarity Pharmaceuticals Provides Update On SECuRE Trial For 8 GBq 67Cu-SAR-bisPSMA Dose Level
05/08	Clarity Pharmaceuticals Says Two New Participants in Prostate Cancer Trial Achieve Complete Response; Shares Jump 14%
31/07	Clarity Plans Phase Three Registrational Study of Neuroendocrine Tumor Treatment Candidate; Shares Jump 12%
16/07	Clarity Pharmaceuticals Limited Announces Appointment of Allison Rossiter as Independent Non-Executive Director
14/05	Clarity Pharmaceuticals Receives AUD 9.8 Million R&D Tax Incentive Refund from Australian Federal Government
30/04	Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting
14/04	Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement with Nucleus Radiopharma
14/04	Australian Shares Rise; Qantas Airways Raises FY26 Fuel Cost Forecast Expectation to Up to AU$3.3 Billion
14/04	Clarity Pharmaceuticals signs commercial manufacturing agreement
14/04	Clarity Pharmaceuticals Enters Manufacturing Deal With Nucleus Radiopharma for Diagnostic Imaging Agent
09/04	Clarity Pharmaceuticals Ltd Announces Colin Biggin Steps Down as Executive Director
31/03	Clarity Pharmaceuticals Publishes Co-PSMA Clinical Trial Data In European Urology Journal
25/03	Clarity signs a large-scale manufacturing supply agreement for copper-64 with Theragenics
25/03	Clarity Pharmaceuticals signs a large-scale manufacturing supply agreement
25/03	Clarity Pharmaceuticals Signs Large-Scale Copper-64 Manufacturing Supply Agreement With Theragenics
17/03	Clarity Pharmaceuticals Ltd Presents Co-PSMA Trial Data And Announces Acceptance For Publication In European Urology
10/03	Clarity Pharmaceuticals Achieves Target Number Of Participants In Phase III Amplify Trial
10/03	Clarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial
02/03	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says
27/02	Clarity Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Income; Shares Jump 13%
26/02	Clarity Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2025
23/02	Clarity Pharmaceuticals Announces SECuRE Trial Update